Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Curious announcement could presage a deal already in place or be an effort to draw competing bids.

You may also be interested in...



Vertex In The Vortex: More Cash, A Bigger Loss And The Departure Of A Key Executive

The drug maker sells future milestone payments for its Hepatitis C drug, but loses its chief commercial officer and head of strategic development.

Vertex In The Vortex: More Cash, A Bigger Loss And The Departure Of A Key Executive

The drug maker sells future milestone payments for its Hepatitis C drug, but loses its chief commercial officer and head of strategic development.

Telaprevir Simmering, Flush Vertex Raises $320 Million More

Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS069683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By